Search

Your search keyword '"Hajime Shimizu"' showing total 291 results

Search Constraints

Start Over You searched for: "Hajime Shimizu" Remove constraint "Hajime Shimizu"
291 results on '"Hajime Shimizu"'

Search Results

251. The (p, d) reactions on A=12–94 nuclei by 65 MeV polarized protons

252. Measurements of analyzing powers for 6− states in 28Si and 24Mg by inelastic scattering of 65 MeV polarized protons

253. Polarization of elastic proton-silicon scattering

255. Architecture and evaluation of a Reduction-based Parallel Inference Machine : PIM-R

256. Evidence for a narrow S = +1 baryon resonance in photoproduction from the neutron

257. Study of non-strange dibaryon resonances via coherent double neutral-pion photoproduction on the deuteron

259. Magnetic properties of metal-doped superconductor YBa 2 (Cu 1−x−y Fe y M x ) 3 O 7−z

260. Magnetic properties and superconductivity of GdBa 2 (Cu 1−x Fe x ) 3 O 7−y

261. Dependence of the Nonresonant Laser Ionization of Rare Gases on Laser Wavelength

263. Defect detection in LiNbO3 crystals using cross Nicol optical system with heating function.

264. Correction: Analyses and architectural typology of preserved traditional mosques in the old city of Herat in Afghanistan: the case of Quzzat Quarter.

265. Delayed Expression of Circulating TGF-β1 and BMP-2 Levels in Human Nonunion Long Bone Fracture Healing.

266. Main Cause of Surface Waveguides Formed under LiNbO3Crystal Surface during Thermal Treatment

267. Eisai's New Leadership.

270. Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute

271. FDA Accepts New Drug Application (NDA) for Rabeprazole Sodium Extended-Release 50 mg for Patients with Gastroesophageal Reflux Disease (GERD)

272. Eisai Expands into Canada

274. FDA Grants Full Approval to ONTAK' (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)

275. U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing

276. Eisai Receives Summary Judgment Motion Decisions in U.S. Legal Action Over Aciphex(R) ANDA Filings

277. Interim 2007 Eisai Earnings Presentation Webcast (English) - Part 2

278. Eisai Acquires Four Oncology-Related Products From Ligand

279. Eisai Commences U.S. Legal Action Over Aricept ODT(R) ANDA Filing

280. FDA Accepts Eisai's sNDA Application for ARICEPT(R) in the Treatment of Severe Alzheimer's Disease

281. Eisai Resubmits sNDA Application for ARICEPT(R) for Treatment of Severe Alzheimer's Disease

282. Eisai Commences U.S. Legal Action over Aricept(R) ANDA Filing

283. Eisai's sNDA Filing for ARICEPT(R) in the Treatment of Severe Alzheimer's Disease Not Accepted by FDA Due to Formatting Deficiencies

287. Eisai Submits Application to FDA for ARICEPT(R) for Treatment of Severe Alzheimer's Disease

288. Eisai Expands into Canada

289. Eisai Completes Acquisition of AkaRx, Inc. and Continues Development of AKR-501 for Thrombocytopenia

290. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application

Catalog

Books, media, physical & digital resources